Celularity vs MaxCyte
CELU and MXCT side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CELU and MXCT compare
MaxCyte is the larger company, worth 4.7 times as much as Celularity ($114M against $24.4M).
MaxCyte grew revenue faster over the last twelve months (−0.13% versus −58.1% for Celularity).
MaxCyte keeps more of each dollar of sales as profit, with a net margin of −81.4% compared with −246% at Celularity.
MaxCyte scores higher on the StockData Score (11 against 7 for Celularity), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CELU | MXCT |
|---|---|---|
| Size and price | ||
| Market cap | $24.4M | $114M |
| Share price | $0.751 | $1.10 |
| Change, 1 year | −57.6% | −25.2% |
| Change, 5 years | −98.9% | −91.4% |
| Beta (5Y) | 1.96 | 1.53 |
| Employees | 115 | 91 |
| StockData Score | ||
| Total score | 7 | 11 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 1 | 1 |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.3× (better) | 3.3× |
| P/B | – | 0.8× |
| FCF yield | – | −18.9% |
| Fair value | – | $3.17 |
| Margin of safety | – | 65.3% |
| Growth | ||
| Revenue growth (TTM) | −58.1% | −0.13% (better) |
| Revenue growth, 5Y average | 13.2% (better) | 4.8% |
| Profitability | ||
| Gross margin | 19.2% | 81.0% (better) |
| Operating margin | −264% | −98.0% (better) |
| Net margin | −246% | −81.4% (better) |
| FCF margin | – | −62.4% |
| Return on equity | – | −16.9% |
| Return on invested capital | – | −42.9% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 0.11 | 7.83 (better) |
| Altman Z-score | −16.46 | 0.31 (better) |
| Piotroski F-score | 1 | 2 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 6.8% | 61.3% |
| Held by insiders | – | 8.0% |
| Insider net buying, 12 months | – | −$8.3K |
| Short interest, % of float | – | 1.7% |
Go deeper
- CELU stock overview
- CELU income statement
- CELU valuation and score
- MXCT stock overview
- MXCT income statement
- MXCT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.